Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Cancerous Battle: Novartis and NATCO clash over Eltrombopag Featured image for Cancerous Battle: Novartis and NATCO clash over Eltrombopag

In a landmark decision, the Delhi High Court overturned an injunction against Natco, allowing them to produce a generic version of Novartis’s cancer drug. The Court held that Novartis’s patent on a specific salt form of the drug (ELT-O) lacked novelty due to its coverage in an earlier patent (IN’176).

Read more about Cancerous Battle: Novartis and NATCO clash over Eltrombopag

Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings

Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings Featured image for Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings

In a recent decision, the Delhi High Court gave clarity about how amended claims during opposition proceedings have to be dealt with by the Controller...

Read more about Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more Featured image for Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

In this week’s patent news: Patent Office notifies Supreme Court’s order on Extensions of Timelines; Patent office announces JPO/IPR Training Course FY 2021; BananaIP and...

Read more about Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more

Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more Featured image for Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more

In this week’s patent news: Natco files compulsory license request for Baricitinib; USA approves temporary patent waiver; EU critical of US proposal for patent waiver,...

Read more about Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more